Neurobiology of Alzheimer´s Disease

Description

• Covers all major aspects of the disease from basic science to clinical diagnosis and therapy
• Written to be accessible and useful to a broad readership of students, researchers, clinicians,and the pharmaceutical industry
• Includes an in-depth analysis of major genes involved in familial Alzheimer's disease; also includes appendices detailing proteins involved, sequences, mutations and known structures
• Therapeutics and the underlying molecular processes of pathogenesis are emphasized

New to this edition

• Includes 3 new extra chapters
• Features 13 new contributors, bringing a fresh perspective
• Includes four totally new topics: inflammation, NGF and the cholinergic system, protein misfolding and amyloid based therapies

Alzheimer's disease is the most common form of dementia in the elderly; 450,000 people in the UK and 4.5 million people in the USA suffer with this disease. This 3rd edition of Neurobiology of Alzheimer's Disease gives a comprehensive and readable introduction to the disease, from molecular pathology to clinical practice.

The book is intended for readers new to the field, and it also covers an extensive range of themes for those with in-depth knowledge of Alzheimer's disease. It will therefore act either as an introduction to the whole field of neurodegeneration or it will help experienced researchers to access the latest research in specialist topics. Each chapter is written by eminent scientists leading their fields in neuropathology, clinical practice and molecular neurobiology; appendices detail disease-associated proteins, their sequences, familial mutations and known structures.

It will be essential reading for students interested in neurodegeneration and for researchers and clinicians, giving a coherent and cohesive approach to the whole area of research, and allowing access at different levels. For those in the pharmaceutical industry it describes the underlying molecular mechanisms involved in the pathogenesis of Alzheimer's disease and explains how current and potential therapeutics may work.

Readership: Medical and life sciences students, clinicians and those working in the pharmaceutical industry.

Contents
1. Alzheimer's disease: a hundred years of investigation , Shelley J Allen
2. The neuropathology of Alzheimer's disease , Margaret M Esiri
3. Molecular genetics of Alzheimer's disease , Alison M Goate
4. Biology and molecular neuropathology of beta-amyloid protein , Edward B Lee & Virginia M-Y Lee
5. The molecular basis of tau protein pathology: role of abnormal hyperphosphorylation , Khalid Iqbal, Alejandra del C Alonso, M Omar Chohan, Ezzat El-Akkad, Cheng-Xin Gong, Sabiha Khatoon, Fei Liu & Inge Grundke-Iqbal
6. Protein misfolding, aggregation and fibril formation: common features of cerebral and non-cerebral amyloidosis , Agueda Rostagno, Ratnesh Lal & Jorge Ghiso
7. Apolipoprotein E, amyloid beta-peptide and Alzheimer's disease , Suzanne E Wahrle & David M Holtzman
8. Presenilins , Kulandaivelu S Vetrivel & Gopal Thinakaran
9. Multiple transgenic mouse models for Alzheimer's disease , Dick Terwel, Ilse Dewachter, Tom van Dooren, Tom Vandebroek, Thomas Van Helmont, David Muyllaert, Peter Borghgraef, Sophie Croes, Joris Winderickx & Fred van Leuven
10. Inflammation and Alzheimer's disease , Mark P Mattson
11. Cellular targets of amyloid beta-peptide: potential roles in neuronal cell stress and toxicity , Xi Chen, David Stern & Shi Du Yan
12. Alzheimer's disease as a neurotransmitter disease , Mitchell K P Lai, Maria J Ramirez, Shirley W Y Tsang & Paul T Francis
13. NGF family of neurotrophins and their receptors: early involvement in the progression of Alzheimer's disease , Elliott J Mufson, Scott E Counts, Margaret Fahnestock & Stephen D Ginsberg
14. Clinical assessment of Alzheimer's disease , Sarmishtha Bhattacharyya, Ros Overshott & Alistair Burns
15. Molecular and biological markers for Alzheimer's disease , Henrik Zetterburg & Kaj Blennow
16. Current pharmacological approaches to treating Alzheimer's disease , Gordon K Wilcock & David Dawbarn
17. Amyloid-based therapies , Weiming Xia
18. Future directions: the A-beta amyloid pathway as the target for diagnosing, preventing or treating Alzheimer's disease , Colin L Masters

Authors, editors, and contributors

Edited by David Dawbarn, Reader in Medicine, University of Bristol, UK and Shelley J. Allen, Sigmund Gestetner Senior Research Fellow in Medicine, University of Bristol, UK

Contributors:Shelley J Allen, Molecular Neurobiology Unit, University of Bristol, Dorothy Hodgkin Bldg, Whitson St, Bristol, UK
Alejandra del C Alonso, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Sarmishtha Bhattacharyya, Wythenshawe Hospital, Manchester, UK
Kaj Blennow, Institute of Clinical Neuroscience, Dep't of Experimental Neuroscience, Sahlgrenska University Hospital, Gotebord University, Goteborg, Sweden
Peter Borghgraef, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven B-3000, Leuven, Belgium
Alistair Burns, Dept of Old Age Psychiatry, Division of Psychiatry, University of Manchester Education and Research Centre, School of Psychiatry and Behavioural Sciences, Wythenshawe Hospital, Manchester, UK
Xi Chen, Dept of Neurology and VA Medical Center, School of Medicine, Saint Louis University, St. Louis, MO, USA
M Omar Chohan, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Scott E Counts, Rush University Medical Center, Dep't of Neurological Sciences, Chicago, IL, USA
Sophie Croes, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Leuven, Belgium
David Dawbarn, Molecular Neurobiology Unit, University of Bristol, Dorothy Hodgkin Bldg, Whitson Street, Bristol, UK
Ilse Dewachter, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Leuven, Belgium
Ezzat El-Akkad, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Margaret M Esiri, Neuropathology Department, Level 1, West Wing, John Radcliffe Hospital, Headington, Oxford, UK
Margaret Fahnestock, Dept of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Paul T Francis, Wolfson Centre for Age-Rrelated Diseases, GKT School of Biomedical Sciences, King's College, London, UK
Jorge Ghiso, Depts of Pathology & Psychiatry, NYU School of Medicine, TH-432, 550 First Avenue, New York, NY, USA
Stephen D Ginsberg, Center for Dementia Research, Nathan Kline Institute, Dep't of Psychiatry, Physiology and Neuroscience, NYU School of Medicine, Orangeburg, USA
Alison M Goate, Dept of Psychiatry, B8134, Washington University School of Medicine, St Louis, MO, USA
Cheng-Xin Gong, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Inge Grundke-Iqbal, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
David M Holtzman, Dept of Neurology, Molecular Biology and Pharmacology, Alzheimer's Disease Research Center and the Hope Center for Neurological Disorders, Washington University School of Medicine, 660 S Euclid, Box 8111, St Louis, MO, USA
Khalid Iqbal, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
John S K Kauwe, Dept of Psychiatry, Washington University, 660 S Euclid, Box 8134, St Louis, MO, USA
Sabiha Khatoon, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Mitchell K P Lai, Wolfson Centre for Age-related Disease, GKT School of Biomedical Sciences, King's College, London, UK, and Dementia Research Laboratory, Dept of Clinical Research, Singapore General Hospital, Singapore
Ratnesh Lal, Centre for Nanomedicine, Dept of Medicine, University of Chicago, MC 6076, Chicago, IL, USA^ Edward B Lee, Center for Neurodegenerative Disease Research, Dep't of Pathology and Laboratory Medicine, HUP Maloney Bldg, 3rd Floor, University of Pennsylvania School of Medicine, 36th and Spruce Streets, Philadelphia, PA, USA
Virginia M-Y Lee, Center for Neurodegenerative Disease Research, Dep't of Pathology and Laboratory Medicine, HUP Maloney Bldg, 3rd Floor, University of Pennsylvania School of Medicine, 36th and Spruce Streets, Philadelphia, PA, USA
Fei Liu, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, USA
Colin L Masters, Dept of Pathology & Mental Health Research Institute, University of Melbourne, Parkville, Victoria 3010, Australia
Mark P Mattson, Laboratory of Neurosciences, National Institute on Aging, Baltimore, MD, USA
Elliott J Mufson, Rush University Medical Center, 1735 W Harrison Street, Suite 300, Chicago, IL, USA
David Muyllaert, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Belgium
Ros Overshott, Trafford NHS Trust, Manchester, UK
Maria J Ramirez, Laboratory of Neuropharmacology, Center for Applied Medical Research (CIMA), School of Medicine, University of Navarra, Pamplona, Spain
Agueda Rostagno, Dept of Pathology, NYU School of Medicine, TH 432, 550 First Avenue, New York, NY, USA
David Stern, Dean's Office, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Dick Terwel, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Leuven, Belgium
Gopal Thinakaran, Dept of Neurobiology, Pharmacology & Physiology, University of Chicago, Knapp R212, 924 East 57th Street, Chicago, IL, USA
Shirley W Y Tsang, Dementia Research Laboratory, Dep't of Clinical Research, Singapore General Hospital, Singapore
Tom Vandebroek, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Leuven, Belgium
Tom van Dooren, Experimental Genetics Group, Dept of Human Genetics, University of Leuven, KU Leuven, B-3000, Leuven, Belgium
Thomas Van Helmont, Laboratory of Functional Biology, KU Leuven, B-3001, Leuven, Belgium
Fred van Leuven, Experimental Genetics Group, Dept of Human Genetics, Campus Gasthuisberg, O&N 1, niv6, KU Leuven, B-3000, Leuven, Belgium
Kulandaivelu S Vetrivel, Dept of Neurobiology, Pharmacology & Physiology, University of Chicago, Knapp R212, 924 East 57th Street, Chicago, IL, USA^ Suzanne E Wahrle, Dept of Neurology, Washington University School of Medicine, 660 S Euclid, Box 8111, St Louis, MO, USA
Gordon K Wilcock, Nuffield Dept of Medicine, University of Oxford, Level 7, John Radcliffe Hospital, Headington, Oxford, UK
Joris Winderickx, Laboratory of Functional Biology, KU Leuven, B-3001, Leuven, Belgium
Weiming Xia, Center for Neurologic Diseases, Harvard Institute of Medicine, HIM 616, 77 Avenue Louis Pasteur, Boston, MA, USA
Shi Du Yan, Dept of Pathology & Surgery, Taub Institute for Research on Alzheimer's Disease and the Ageing Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Henrik Zetterburg, Institute of Clinical Neuroscience, Dep't of Experimental Neuroscience, Salgrenska University Hospital, S-431 80 Goteborg, Sweden